BCLI

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) is a biotechnology company founded in 2000 and incorporated in New York. Originally established as Golden Hand Resources Inc., the company changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 and went public in October 2003. The company specializes in developing autologous cellular therapies for neurodegenerative diseases, with its flagship product NurOwn currently in late-stage clinical trials for amyotrophic lateral sclerosis (ALS). Brainstorm has faced significant financial challenges in recent years, operating with minimal cash reserves while pursuing regulatory approval for its lead therapy.